Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels:: aggressive or insignificant?

被引:38
作者
Gosselaar, C [1 ]
Roobol, MJ [1 ]
Schröder, FH [1 ]
机构
[1] Erasmus Univ, Dept Urol, Screening Unit Prostate Canc, NL-3000 CA Rotterdam, Netherlands
关键词
D O I
10.1111/j.1464-410X.2005.05324.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Screening for prostate cancer at low prostate-specific antigen (PSA) levels (less than or equal to4.0 ng/mL) risks detecting clinically insignificant cancers, which are of no threat to the man. In this review we evaluate the prevalence and tumour characteristics of prostate cancer detected at low PSA levels, comparing screening studies, cystoprostatectomy series and autopsy data. The favourable characteristics of tumours detectable at very low PSA levels seem to justify the conclusion that an unknown but sizeable proportion of the cancers found at biopsy are clinically insignificant.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 53 条
[1]   LATENT CARCINOMA OF THE PROSTATE [J].
ANDREWS, GS .
JOURNAL OF CLINICAL PATHOLOGY, 1949, 2 (03) :197-208
[2]  
Beemsterboer PMM, 1999, INT J CANCER, V84, P437, DOI 10.1002/(SICI)1097-0215(19990820)84:4<437::AID-IJC19>3.0.CO
[3]  
2-S
[4]  
BOGDANOWICZ JFAT, 1991, SCAND J UROL NEPHROL, P97
[5]   Prostate cancers in men with low PSA levels - Must we find them? [J].
Carter, HB .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (22) :2292-2294
[6]   Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements [J].
Catalona, WJ ;
Smith, DS ;
Ornstein, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1452-1455
[7]   Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen [J].
Catalona, WJ ;
Bartsch, G ;
Rittenhouse, HG ;
Evans, CL ;
Linton, HJ ;
Horninger, W ;
Klocker, H ;
Mikolajczyk, SD .
JOURNAL OF UROLOGY, 2004, 171 (06) :2239-2244
[8]  
EDWARDS CN, 1953, CANCER, V6, P531, DOI 10.1002/1097-0142(195305)6:3<531::AID-CNCR2820060311>3.0.CO
[9]  
2-9
[10]   PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374